{"id":390945,"date":"2017-07-17T00:00:00","date_gmt":"2017-07-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0042-2017-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-us-2017\/"},"modified":"2026-05-04T23:26:13","modified_gmt":"2026-05-04T23:26:13","slug":"algoim0042-2017-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0042-2017-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-us-2017\/","title":{"rendered":"Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | US | 2017"},"content":{"rendered":"<p>MARKET OUTLOOK The primary goal of UC treatment is to induce and maintain remission with little to no clinical symptoms remaining. Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate patients, whereas IV and subcutaneous TNF-a inhibitors are primarily reserved for moderate to severe patients refractory to conventional treatment or for first-line treatment in the most severe patients. Lack of primary response or loss of response to TNF-a inhibitors is an ongoing concern; however, the IV-delivered CAM inhibitor Entyvio is a recent entry to the treatment armamentarium that offers an alternative mechanism of action for these patients, and has lead to increasing competition among the biologics.<br \/>\n<strong>QUESTIONS ANSWERED \u00b7<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed ulcerative colitis patients?<\/li>\n<li>What are the quarterly trends in prescribing among recently-treated and new diagnosed ulcerative colitis patients? \u00a0<\/li>\n<li>How has Enyvio been integrated into the treatment algorithm? \u00a0<\/li>\n<li>What proportion of ulcerative colitis patients receive drug therapy within 365 days of diagnosis, and how quickly?<\/li>\n<li>What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of ulcerative colitis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies? \u00a0<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with ulcerative colitis?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390945","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ulcerative-colitis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390945\/revisions"}],"predecessor-version":[{"id":394069,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390945\/revisions\/394069"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}